Article Summary
Cosmetic plastic surgery practices brag about 70%+ gross margins. Most still net 12–18% operating margin once you classify costs honestly. The gap between those two numbers is where the practice leaks money — and where the 60-15-15 diagnostic finds it. The 2026 target for a healthy plastic surgery practice is a 30% operating margin, built from a 60% gross margin, 15% sales and marketing, and 15% general and administrative spend. Below 20%, you’re working harder every year to stay in the same place. This is the math, the diagnostic sequence, and the multiple gap on sale.
The number that actually matters isn’t gross margin — it’s operating margin
A healthy plastic surgery practice in 2026 hits 30% operating margin. Most sit at 12–18%. The gap is structural, not effort.
Here’s the disconnect: cosmetic-focused practices routinely report gross margins above 70% because surgical procedures carry high price tags and direct supply costs are low relative to ticket size. According to Madison Plastic Surgery’s economic analysis, cosmetic-heavy practices commonly exceed 70% gross margin when surgery is the primary revenue source. That number gets repeated at conferences and in surgeon Facebook groups until it feels like a benchmark.
It isn’t a benchmark. It’s a vanity number.
According to the Medical Group Management Association, the average U.S. medical practice runs at roughly a 17.5% EBITDA margin. Plastic surgery is supposed to be the high-margin specialty. So why does the operating margin land in roughly the same range as a primary care clinic?
Because gross margin is bragging rights. Operating margin is what pays you.
Think of it like this: out of every dollar that comes through the door, how much is left after paying everyone who touched the case, everyone who brought the patient in, and everyone who keeps the lights on? If it’s less than 30 cents, your practice is busy — not profitable.
Bennett Financials is a fractional CFO and tax planning firm that helps service business founders doing $1M–$20M diagnose growth bottlenecks, fix margins, and build businesses worth selling. I run the same diagnostic on every practice that comes in: where is operating margin actually landing, and which of the three buckets is leaking?
Why “70% gross margin” is misleading you
Most surgeons calculate gross margin as revenue minus implants, sutures, and disposables. That’s not gross margin. That’s contribution after consumables.
What the 70% number actually counts (and what it leaves out)
Real gross margin in a service practice is revenue minus everything required to deliver the procedure. For a plastic surgery practice that means:
- Surgeon time (the portion of compensation tied to delivering cases, not running the business)
- OR staff and recovery nurses
- Anesthesia (if employed; pass-through if contracted)
- Supplies, implants, disposables
- Facility cost per case (the percentage of rent, utilities, and equipment depreciation tied to the OR and clinical space)
When you classify costs honestly, cosmetic gross margin lands at 55–65% — not above 70%. Reconstructive-heavy practices land lower because of insurance reimbursement compression. The office-based surgical suite cost analysis published in Plastic and Reconstructive Surgery — Global Open put the average plastic surgery case cost at $1,202.80 even before pricing in surgeon delivery time — and that was nearly a decade ago, before EHR mandates and facility certification requirements added another layer of fixed cost.
If your books say 75% gross margin, the costs are sitting somewhere else on the P&L.
The cost categories most practices misclassify
Three places it usually hides:
- Surgeon compensation. If the owner-surgeon takes a $400K salary plus distributions and the entire salary lives in administrative overhead, gross margin looks artificially clean and G&A looks impossible. The honest split: track time for two to four weeks, then allocate proportionally across delivery (COGS), sales (S&M), and leadership (G&A). A surgeon who spends 60% of their time operating, 20% in consults, and 20% running the business should see their comp split 60/20/20 across the three buckets.
- Patient coordinators. They’re sales staff, not admin. If they’re booking consults and converting them into procedures, their salary belongs in S&M.
- Marketing spend buried under “office supplies” or “professional services.” Google Ads, Instagram management, photographer retainers, and event sponsorships all live in S&M. When they’re scattered across other line items, the practice sees a lower S&M ratio than reality.
Until classification is right, every benchmark is wrong.
The 60-15-15 standard applied to plastic surgery practices
Picture a $5M cosmetic practice — one surgeon, two injectors, four support staff. Cash-pay, aesthetic-heavy, light reconstructive volume. Here’s the target:
| Metric | Target | What it means |
|---|---|---|
| Gross Margin | 60% | After all delivery costs (surgeon delivery time, OR staff, supplies, facility per case) |
| S&M | ≤15% | All sales and marketing — coordinators, ad spend, agency, events |
| G&A | ≤15% | Rent, admin staff, EHR, insurance, leadership comp portion |
| Operating Margin | 30% | The destination |
This is the destination, not the starting line. Timeline to get there from a typical starting position: 18–24 months of focused execution.
Where most practices actually start
| Revenue | Typical GM | S&M | G&A | Operating |
|---|---|---|---|---|
| $1M–$3M | 50–58% | 20–28% | 28–38% | breakeven to 10% |
| $3M–$5M | 55–62% | 18–25% | 22–30% | 8–15% |
| $5M–$10M | 58–65% | 15–22% | 18–25% | 12–20% |
| $10M–$20M | 60–68% | 12–18% | 15–22% | 18–28% |
The 30% destination is universal. The timeline isn’t. A $1.5M practice running 35% G&A isn’t failing — they have a starting point. A $12M practice running 25% G&A is leaving real money on the table.
Where the margin leaks — the diagnostic sequence
The sequence is fixed: COGS → S&M → G&A. Never reordered.
This matters because pricing fixes flow downstream automatically. Raise pricing 30% and revenue grows without proportional cost growth — which means S&M and G&A shrink as a percentage of revenue without you cutting a single dollar. Cut admin first and you’ve solved nothing structural; the margin pressure rebuilds in 12 months.
COGS first — the close-rate signal
Close rate is a pricing signal before it’s a sales metric. The bands:
- Close rate above 80% — pricing is too low. Triple it. Yes, triple. Practices in this band are leaving more on the table than they realize, and the close rate will settle into the 35–45% range at the new price point with the same gross revenue or higher.
- Close rate 60–80% — double or 1.5x.
- Close rate 50–60% — raise 50–100%.
- Close rate 30–40% — pricing is right. The leak is somewhere else (labor efficiency, mix, or no-shows).
- Close rate below 30% — sales or qualification problem, not pricing.
Once pricing is in band, run the labor efficiency check. The rule is 3.5x minimum, calculated as revenue divided by all delivery labor (surgeon delivery time, OR staff, recovery, contracted anesthesia). Three-and-a-half because below that the math stops working — at 2.5x you’re effectively trading dollars for surgeon hours; above 5x you usually have either a pricing tailwind or under-staffed delivery that will catch up to you on outcomes. The 3.5–5x band is where most healthy practices live.
S&M second — the two gates
If S&M is over 15% of revenue, run the two gates before cutting anything:
- LTV:CAC at least 4:1 — lifetime value of a patient (across procedures, injectables, follow-up surgery) divided by cost to acquire that patient.
- CAC payback under 6 months — how fast does the patient’s first procedure recoup the acquisition cost?
In plastic surgery, retention is the lever. First procedure → injectables maintenance → follow-up surgery is the LTV path. A practice that converts a $12K rhinoplasty patient into a $2,400/year injectables patient for the next decade has a fundamentally different LTV math than a practice that does one procedure and never sees the patient again. If both gates are green, S&M over 15% is growth investment — keep scaling. If either gate is red, you don’t have a spend problem. You have an economics problem. Cutting spend without fixing economics shrinks the top line and leaves margin worse.
G&A third — what it usually is
Three places G&A bloats:
- Owner-surgeon comp misclassified. Cover the time-tracking allocation above and 3–6 points usually move out of G&A automatically.
- Office and facility creep. Practices grow into bigger spaces during good years and never right-size when growth flattens. Worth 2–4 points.
- Admin headcount that should have been automation. EHR add-ons, scheduling tools, and patient communication platforms cost $5K–$10K per year and replace $60K admin roles. Automate first, then consolidate.
For most practices, fractional CFO support for service practices is what makes the difference between knowing the diagnostic and actually executing it on a 90-day cadence.
Want to know where your business sits against the 60-15-15 standard? The Scale-Ready Assessment runs your actual numbers, builds a custom tax strategy, and produces a full enterprise value report. Free for US-based service businesses doing $1M–$20M. Book your free Assessment — 15 spots per month.
The owner-surgeon trap
Plastic surgery is the highest-leverage version of “the owner IS the business.” Patients book the surgeon by name. The brand walks out the door if the surgeon does. The reviews, the before-and-afters, the Instagram following — all attached to one person.
This is also the single biggest enterprise value killer in this category.
According to SalaryDr’s 2026 verified compensation data, the median plastic surgeon earns $750,000, with top 90th-percentile earners reaching $4M. But that earning power is the surgeon’s — not the practice’s. When the surgeon retires or sells, most of it walks out with them unless the practice has been deliberately structured to detach the brand from the individual.
The fix is structural, not promotional. Three layers:
- Layered providers. PAs, NPs, and second surgeons handle injectables, follow-ups, and a meaningful share of consults. Patients meet “the practice” before they meet “the surgeon.”
- Procedural systemization. Documented consult scripts, surgical protocols, and post-op standards that produce consistent outcomes regardless of which provider executed.
- Brand separate from surgeon. The practice’s marketing, name, and review profile is built on the practice — not the founder’s personal Instagram. This one is the hardest because it requires the founder to step out of the spotlight while the practice is still growing under their name.
In my client base, owner dependence is almost always the single biggest unlock for the practices that want to sell in the next five years. It’s also the slowest fix — 12 to 18 months minimum.
What this means on sale — the multiple math
Plastic surgery is one of the most active healthcare M&A categories right now. According to FOCUS Investment Banking’s 2026 valuation analysis, plastic surgery transaction volume rose from 5 deals in 2022 to 27 in 2024 — a top-quartile category within physician services M&A. Cash-pay aesthetics plus commercial-payer mix is what makes the category attractive.
Multiples in 2026:
- Platform-ready cosmetic-heavy practices: 9–12x EBITDA
- Top-tier multi-state cosmetic platforms: 12–15x+
- The $3M EBITDA threshold is the inflection point — below it, you’re a local add-on; above it, you’re platform-ready, where multiples expand by 2–4 turns.
Here’s the worked example for the $5M cosmetic practice:
- Practice A: $5M revenue, 15% operating margin = $750K EBITDA. At a 4x multiple (single-surgeon, owner-dependent), enterprise value = $3M.
- Practice B: $5M revenue, 28% operating margin = $1.4M EBITDA. At a 7x multiple (layered providers, lower owner dependence), enterprise value = $9.8M.
Same revenue. Same patient base. Same surgeon. The structural difference is worth $6.8M on sale.
This is the tax planning and enterprise value gap together — proactive tax strategy keeps more EBITDA in the practice while operational maturity expands the multiple. Both compound.
Case study: from bookkeeping to operational maturity
Different industry, identical dynamics. NuSpine is a chiropractic practice — practitioner-dependent, service-delivered, valuation tied to operational maturity rather than procedure volume. Same trap as a plastic surgery practice: the owner is the brand, the books look fine, and growth runs on instinct.
The pain. Bookkeeping wasn’t providing direction. No financial roadmap. The practice was growing, but every decision — hire, expand, raise prices, take distributions — was being made on gut feel.
What we did. Strategic CFO support, not just monthly close. Clear goals, benchmarks, and accountability. We built a long-term wealth roadmap with milestones and timelines that connected practice profitability to the owner’s personal financial trajectory.
The friction. The owner was initially skeptical that financial strategy would change outcomes. Bookkeeping had been the relationship for years. The shift from “report what happened last month” to “decide what’s going to happen next quarter” took deliberate effort on both sides.
The result. Financial clarity enabled a clean exit from the operator role. Exit capital funded franchise acquisitions — the owner moved from operator to owner/investor.
The translatable insight for a plastic surgery practice: wealth comes from a long-term plan with milestones, not from random financial moves between consultations. The same pattern shows up across the plastic surgery practices I work with — owner-surgeons who realize the value isn’t in the next case, it’s in the structure that lets the next case happen without them.
Book a free Scale-Ready Assessment — three deliverables: full 60-15-15 financial diagnostic, a tax plan, and an enterprise value report showing your current multiple and the gap. 15 spots per month.
